Antibody, Immune Response, Regulation and RNA

Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical

Delveinsight

SEPTEMBER 23, 2021

The biotech has evolved a T-cell receptor-like antibody to damage a selected immune checkpoint in oncology. Abexxa is forming molecules, which recruit immune cells zeroed in on particular tumor peptides. 858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Jeffrey Stafford, Ph.D., Stafford and co.

RNA

RNA Gene Therapy Gene Protein

Gritstone bio trumpets first data for ‘multivariant’ COVID jab

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. “With new variants – like Omicron and B.1.640.2

Protein

Protein Vaccination Vaccine Immune Response

Sanofi and GlaxoSmithKline Reenter COVID-19 Vaccine Race With Phase 2 Results | 2021-05-17

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. And if the results are positive, the companies expect to seek approval from regulators in the fourth quarter. 14, 2020 ). 2 infection.

Vaccination

Vaccination Vaccine Immune Response RNA

Race for COVID-19 vaccine hots up as EMA begins review of BioNTech/Pfizer jab

pharmaphorum

OCTOBER 6, 2020

The announcement comes just days after the regulator said its CHMP scientific committee had begun to look at the first batch of data from AZ’s rival. These studies suggest BNT162b2 triggers the production of neutralising antibodies and T-cells that target SARS-CoV-2, the coronavirus that causes COVID-19.

Vaccination

Vaccination Vaccine RNA Immune Response

Cash round sets up trial of InteRNA’s microRNA for cancer

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells.

Trials

Trials Gene Silencing RNA Gene Expression

Next Generation RNA Therapeutics and Vaccines – A Marvel of The Lifesciences Industry

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA

RNA Vaccination Vaccine Development

Discovery could lead to more efficient cancer therapies

Drug Discovery World

JUNE 27, 2023

Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity. CD8+ T cells have been the focal point of anti-cancer therapies.

Regulation

Regulation Antibody Scientist Immune Response

Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Antibody

Antibody Sales Production Development

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein

Protein Antibody Engineer Scientist

Will Vaccines Work Against the New Coronavirus Variants?

The Pharma Data

JANUARY 21, 2021

.” But the Pfizer and Moderna vaccines are designed to not only target the spike protein, but to promote the creation of antibodies that will attack it in several different ways, Salvatore said. “The height of the antibody response may be somewhat proportional to how sick you are in the beginning.

Vaccination

Vaccination Vaccine Protein Immune Response

Biopharma Leaders Unite To Stand With Science

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Vaccination

Vaccination Vaccine Containment Clinical Trials

Biopharma Leaders Unite To Stand With Science

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. For more information, visit. www.merck.com. and connect with us on. the United States.

Vaccination

Vaccination Vaccine Containment Clinical Trials

Organ-on-a-chip models in drug development

Drug Discovery World

APRIL 12, 2023

According to a McKinsey & Company article 2 , new drug modalities (such as RNA therapeutics, protein degraders, cyclopeptides, ADCs, cell and gene therapies) have almost doubled from 11% to 21% of the drug pipeline. For some pharmaceutical companies, like AstraZeneca 3 , 30% of their early pipeline consists of new drug modalities.

Development

Development In-Vivo Drugs In-Vitro

Organ-on-a-chip models in drug development

Drug Discovery World

JANUARY 20, 2023

According to a McKinsey & Company article 2 , new drug modalities (such as RNA therapeutics, protein degraders, cyclopeptides, ADCs, cell and gene therapies) have almost doubled from 11% to 21% of the drug pipeline. For some pharmaceutical companies, like AstraZeneca 3 , 30% of their early pipeline consists of new drug modalities.

Development

Development In-Vivo Drugs In-Vitro

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. This design protects antibodies from the innate immune system. Langer, now a David H.

Drug Delivery

Drug Delivery Vaccination Vaccine Research

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccination

Vaccination Vaccine Antibody Life Science

Clinical Research Informer

Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical

Gritstone bio trumpets first data for ‘multivariant’ COVID jab

Trending Sources

Sanofi and GlaxoSmithKline Reenter COVID-19 Vaccine Race With Phase 2 Results | 2021-05-17

Race for COVID-19 vaccine hots up as EMA begins review of BioNTech/Pfizer jab

Cash round sets up trial of InteRNA’s microRNA for cancer

Next Generation RNA Therapeutics and Vaccines – A Marvel of The Lifesciences Industry

Discovery could lead to more efficient cancer therapies

Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance

What to expect from PEGS Europe 2023: Day 3

Will Vaccines Work Against the New Coronavirus Variants?

Biopharma Leaders Unite To Stand With Science

Biopharma Leaders Unite To Stand With Science

Organ-on-a-chip models in drug development

Organ-on-a-chip models in drug development

Covid-19 vaccine success bolsters nanoparticle drug delivery research

COVID-19 Pandemic Coverage

Stay Connected